Type of information: Licensing agreement
Company: BMS (USA - NY) Biogen (USA - CA)
Therapeutic area: Rare diseases - Neurodegenerative diseases - Neurological diseases
Type agreement: licensing
Action mechanism: monoclonal antibody. BMS-986168 is a monoclonal antibody designed to bind to and decrease levels of extracellular Tau (eTau) protein. It is currently being investigated as a treatment option for patients with PSP, with the potential for future development in other neurodegenerative diseases such as Alzheimer’s disease.
Disease: progressive supranuclear palsy
Details: • On April 13, 2017, BMS announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for progressive supranuclear palsy (PSP), to Biogen.
Financial terms: Under the agreement to license BMS-986168, Biogen will pay to BMS an upfront payment of $300 million with potential milestone payments of up to $410 million. Biogen also will assume all remaining obligations to the former stockholders of iPierian, Inc. related to BMS’ acquisition of the company in 2014.